Holen Sie sich die Stockscreener-App
4.32
2.27%
-0.09
Schlusskurs vom Vortag:
$4.41
Offen:
$4.41
24-Stunden-Volumen:
18,365
Relative Volume:
0.06
Marktkapitalisierung:
$40.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+3.11%
1M Leistung:
+6.95%
6M Leistung:
-82.49%
1J Leistung:
+0.00%
1-Tages-Spanne:
$4.285
$4.42
1-Wochen-Bereich:
$4.13
$4.71
52-Wochen-Spanne:
$3.74
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Firmenname
Tvardi Therapeutics Inc
Sektor
Branche
Telefon
(713) 489-8654
Adresse
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Vergleichen Sie TVRD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
4.31 | 41.37M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.76 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.16 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
845.14 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.53 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.78 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-14 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-10-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-10-13 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-13 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-14 | Eingeleitet | Raymond James | Outperform |
| 2025-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-12 | Eingeleitet | Piper Sandler | Overweight |
| 2025-05-21 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-15 | Eingeleitet | BTIG Research | Buy |
| 2024-06-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | Herabstufung | Needham | Buy → Hold |
| 2024-06-13 | Herabstufung | Stifel | Buy → Hold |
| 2023-03-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-11-01 | Fortgesetzt | Canaccord Genuity | Buy |
| 2021-08-03 | Eingeleitet | JP Morgan | Neutral |
| 2020-04-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-29 | Bestätigt | Laidlaw | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2019-01-15 | Eingeleitet | BofA/Merrill | Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Eingeleitet | Jefferies | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2018-02-12 | Hochstufung | Janney | Neutral → Buy |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
Alle ansehen
Tvardi Therapeutics Inc Aktie (TVRD) Neueste Nachrichten
What analysts say about Tvardi Therapeutics Inc stockCash Flow Trends & Affordable Portfolio Growth - earlytimes.in
Tvardi Therapeutics Advances STAT3 Inhibitor Clinical Trials - MSN
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics - PR Newswire
Tvardi Therapeutics (TVRD) Price Target Decreased by 24.64% to 15.15 - MSN
How Low Can Tvardi Therapeutics Stock Really Go? - Trefis
Tvardi Therapeutics (TVRD) Stock Analysis Report | Financials & Insights - Benzinga
Will Tvardi Therapeutics Inc. (69C) stock outperform value peersJuly 2025 Weekly Recap & Free Daily Entry Point Trade Alerts - Newser
Can Tvardi Therapeutics Inc. stock sustain institutional interestTrade Exit Summary & Detailed Earnings Play Alerts - Newser
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics - Barchart.com
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims On Behalf Of Investors Of Tvardi Therapeutics - Menafn.com
Is Tvardi Therapeutics Inc. (69C) stock trading at attractive multiplesChart Signals & Fast Exit and Entry Trade Guides - Newser
Why Tvardi Therapeutics Inc. (69C) stock could outperform next yearWeekly Profit Analysis & Technical Pattern Recognition Alerts - Newser
With Tvardi Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
Will Tvardi Therapeutics Inc. (69C) stock see insider accumulationJuly 2025 Big Picture & Low Drawdown Trading Techniques - Newser
How big funds are accumulating Tvardi Therapeutics Inc. (69C) stockJuly 2025 Trends & Free Real-Time Market Sentiment Alerts - Newser
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims o - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Tvardi Therapeutics - The National Law Review
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics - GlobeNewswire
Why retail investors favor Tvardi Therapeutics Inc. stockWeekly Trade Report & Capital Protection Trading Alerts - moha.gov.vn
Tvardi Therapeutics (NASDAQ:TVRD) Stock Rating Upgraded by Wall Street Zen - Defense World
Tvardi Therapeutics: Buy Rating Reaffirmed Amid Upcoming Catalysts and Risk-Reward Scenario - TipRanks
Will Tvardi Therapeutics Inc. (69C) stock enhance shareholder value2025 Momentum Check & Smart Money Movement Tracker - newser.com
Can Tvardi Therapeutics Stock Recover If Markets Fall? - Trefis
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
How Tvardi Therapeutics Inc. (69C) stock reacts to stronger dollarPortfolio Profit Report & AI Forecast for Swing Trade Picks - newser.com
Is Tvardi Therapeutics Inc. stock ready for a breakoutPortfolio Performance Summary & Capital Protection Trading Alerts - newser.com
Will Tvardi Therapeutics Inc. benefit from macro trendsJuly 2025 Weekly Recap & Weekly Breakout Stock Alerts - newser.com
Can Tvardi Therapeutics Inc. (69C) stock expand revenue streamsJuly 2025 Reactions & Safe Capital Growth Tips - newser.com
What valuation ratios show for Tvardi Therapeutics Inc. (69C) stockJuly 2025 Big Picture & Trade Opportunity Analysis - newser.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Tvardi Therapeutics, Inc. (TVRD) And Encourages Shareholders to Connect - ACCESS Newswire
Can Tvardi Therapeutics Inc. (69C) stock deliver double digit returnsRisk Management & Weekly Chart Analysis and Trade Guides - newser.com
How to interpret RSI for Tvardi Therapeutics Inc. stockJuly 2025 Retail & Daily Chart Pattern Signals - newser.com
Tvardi Therapeutics, Inc. Updates on Clinical Trials and Pipeline Progress - TradingView
How Tvardi Therapeutics Inc. stock reacts to global recession fearsEarnings Summary Report & Long-Term Capital Growth Ideas - newser.com
Finanzdaten der Tvardi Therapeutics Inc-Aktie (TVRD)
Es liegen keine Finanzdaten für Tvardi Therapeutics Inc (TVRD) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.56%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):